Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 4/20 | 0.59 |
| ▸ | POLB | P06746 | 3/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.49 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.49 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.48 |
| ▸ | JAK2 | O60674 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29707284 | 1.00 | ACE (0.59) | ACEPOLBTDP1L3MBTL1HDAC8 | |
| SCHEMBL66871 | 1.00 | ACE (0.59) | ACEPOLBTDP1L3MBTL1HDAC8 | |
| SCHEMBL29401053 | 1.00 | ACE (0.59) | ACEPOLBTDP1L3MBTL1HDAC8 | |
| SCHEMBL14067913 | 1.00 | ACE (0.59) | ACEPOLBTDP1L3MBTL1HDAC8 | |
| SCHEMBL2080858 | 1.00 | ACE (0.59) | ACEPOLBTDP1L3MBTL1HDAC8 | |
| SCHEMBL6240970 | 0.87 | PTPN1 (0.48) | ACEHDAC8PTPN1 | |
| SCHEMBL1791198 | 0.87 | UCHL1 (0.48) | ACEPOLBTDP1 | |
| SCHEMBL26748805 | 0.87 | ACE (0.57) | ACEPOLBTDP1L3MBTL1CHEK1 | |
| SCHEMBL21490343 | 0.86 | PTPN1 (0.65) | HDAC8PTPN1 | |
| SCHEMBL29443079 | 0.86 | PTPN1 (0.65) | HDAC8PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 504 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103145797-B | [(3s)-1,2,3,4-tetrahydroisoquinoline-3-formoxy]-Lys modified RGD tetrapeptide and its synthesis method and use in medical science | UNIV CAPITAL MEDICAL SCIENCES | 2015-05-20 | — | — | CN | claimed |
| CN-103145797-A | [(3s)-1,2,3,4-tetrahydroisoquinoline-3-formoxy]-Lys modified RGD tetrapeptide and its synthesis method and use in medical science | UNIV CAPITAL MEDICAL | 2013-06-12 | — | — | CN | claimed |
| US-20090298870-A1 | PODOPHYLLOTOXIN DERIVATIVES | Sutter West Bay Hospitals, dba California Pacific Medical Center and Catholic Healthcare West | 2009-12-03 | — | — | US | claimed |
| EP-3706747-B1 | PRMT5 INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2025-09-03 | — | — | EP | disclosed |
| US-20250214977-A1 | STAT6 INHIBITORS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-07-03 | — | — | US | disclosed |
| EP-4534524-A1 | AMINO ACID ACTIVE ESTER AND SALT THEREOF | PeptiDream Inc. (JP) | 2025-04-09 | — | — | EP | disclosed |
| WO-2024110758-A2 | NATURAL KILLER CELLS | NK:IO Ltd (GB) | 2024-05-30 | — | — | WO | disclosed |
| CN-114728938-B | Tetrahydroisoquinoline spiro compounds as PRMT5 inhibitors | 南京再明医药有限公司 | 2024-05-24 | — | — | CN | disclosed |
| US-11952365-B2 | Anti-viral compounds | ALIGOS THERAPEUTICS, INC. (US) | 2024-04-09 | — | — | US | disclosed |
| CN-117486762-A | Novel compound and use method and application thereof | 中国医学科学院医药生物技术研究所 | 2024-02-02 | — | — | CN | disclosed |
| EP-4304588-A1 | COMPOUNDS HAVING TETRAHYDROINDOLIZINE-1-CARBOXAMIDE AS BCL-2 INHIBITORS | Eil Therapeutics, Inc. (US) | 2024-01-17 | — | — | EP | disclosed |
| EP-0618221-A2 | Heterocyclic inhibitors of farnesyl protein transferase | BRISTOL-MYERS SQUIBB COMPANY (US) | 1994-10-05 | — | — | EP | disclosed |
| WO-1994005310-A1 | PEPTIDE INHIBITORS OF CELLULAR ADHESION | CENTOCOR, INC. (US) | 1994-03-17 | — | — | WO | disclosed |
| CN-1071930-A | Inhibitor as the human immunodeficiency virus protease who treats acquired immune deficiency syndrome (AIDS) | LILLY CO ELI (US) | 1993-05-12 | — | — | CN | disclosed |
| EP-0526009-A1 | Inhibitors of hiv protease useful for the treatment of aids | ELI LILLY AND COMPANY (US) | 1993-02-03 | — | — | EP | disclosed |
| EP-0504064-A1 | Novel thrombin inhibitors | MERRELL PHARMACEUTICALS INC. (US) | 1992-09-16 | — | — | EP | disclosed |
| US-5142056-A | Human immunodeficiency virus protease inhibitor | ABBOTT LABORATORIES (US) | 1992-08-25 | — | — | US | disclosed |
| EP-0490667-A2 | HIV protease inhibitors | JAPAN ENERGY CORPORATION (JP) | 1992-06-17 | — | — | EP | disclosed |
| US-5047400-A | Treatment of infection; antitumor agents | ADIR ET CIE (FR) | 1991-09-10 | — | — | US | disclosed |
| EP-0402646-A1 | Retroviral protease inhibiting compounds | ABBOTT LABORATORIES (US) | 1990-12-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11952365-B2 | Anti-viral compounds | EIF2AK2, ZC3HAV1, HAVCR2 | ACE 7/4885POLB 356/4885TDP1 2526/4885 |
| US-20250214977-A1 | STAT6 INHIBITORS AND USES THEREOF | STAT6, STAT5B, STAT5A | ACE 1000/4885POLB 4132/4885TDP1 3611/4885 |
| US-20090298870-A1 | PODOPHYLLOTOXIN DERIVATIVES | APEH, DAGLA, DPY30 | ACE 4001/4885POLB 3645/4885TDP1 1322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.